Seven Eight Capital, LP Crispr Therapeutics Ag Transaction History

Seven Eight Capital, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$60.67 - $89.12 $1.03 Million - $1.52 Million	-17,032 Reduced 57.63%	12,524 $853,000
Q4 2023 Feb 13, 2024	BUY	$38.62 - $72.18 $516,619 - $965,551	13,377 Added 82.68%	29,556 $1.85 Million
Q3 2023 Nov 14, 2023	BUY	$45.39 - $59.0 $734,364 - $954,561	16,179 New	16,179 $734,000
Q3 2022 Nov 10, 2022	BUY	$61.1 - $83.78 $510,918 - $700,568	8,362 New	8,362 $546,000

485

57.5M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.12B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.